Di-san junyi daxue xuebao (Aug 2019)
Effect of tigecycline on coagulation markers: a retrospective study
Abstract
Objective To determine the effect of tigecyclin on coagulation markers in the patients taking it, and screen out the related risk factors. Methods A retrospective study was carried out on the patients with tigecycline treatment admitted to our hospital from January 2016 to December 2017 based on our hospital information system and the Meikang rational drug use monitoring system. Fibrinogen (FBG) level, prothrombin time (PT), activated partial thromboplastin time (APTT), thrombin time (TT), platelet (PLT) count, glomerular filtration rate (eGFR), and levels of alanine aminotransferase (ALT) and serum total bilirubin (TBIL) were compared before and after tigecycline administration. Finally, according to whether patients had abnormal coagulation indicators, Logistic regression was used to screen out high-risk factors of abnormal coagulation indexes caused by tigecycline. Results A total of 97 qualified cases were included in this study, including 69 males (71.1%) and 28 females (28.9%), at a mean age of 56.93±19.31 years. Tigecycline treatment resulted in significantly decreased FBG level (P < 0.05) and prolonged PT, APTT and TT (P < 0.05), but no such change was seen in PLT count. At the same time, there were no significant differences in ALT and TBIL levels before and after administration, and CRP and PCT showed significant differences (P < 0.05), while WBC count showed no significant difference. The total WBC count, and CRP and PCT levels were decreased after administration, indicating the patients' infection status was improved. The eGFR value was remarkably improved (P < 0.05), indicating better renal function. Logistic analysis showed that high dose of tigecycline was a risk factor for coagulopathy (P < 0.05, OR=3.96). Conclusion Tigecycline may cause decreased FBG, prolonged PT, APTT and TT, and the patients taking high dose tigecycline are prone to this adverse event.
Keywords
